McCormick Proposed Doubling National NIH Budget
The plan aims to revitalize stagnant research funding and mandates new financial disclosures for academic scientists.
Updated on Sept. 23, 2026 in Healthcare
Live Poll
Should the federal government double its investment in scientific research to drive medical innovation?
Senator Dave McCormick has proposed doubling the $48 billion National Institutes of Health budget over five years to spur long-term innovation. The proposal includes new transparency rules for federally funded researchers and aims to address the nation's $5.3 trillion health bill.
Why it matters
Federal R&D spending has dropped from 1.86 percent of GDP in 1964 to 0.63 percent in 2024, leaving foundational science projects vulnerable to funding gaps. McCormick argues that private capital cannot sustain the long-term horizons required for breakthrough research.
The NIH budget currently totals $48 billion, which represents a decline of more than 10% since 2003 after adjusting for inflation. Additionally, federal R&D spending as a share of GDP has fallen to 0.63 percent in 2024 from 1.86 percent in 1964.
The players
Dave McCormick
United States Senator who is promoting legislation to increase federal funding for medical research.
National Institutes of Health
The primary federal agency responsible for biomedical and public health research in the United States.
University of Pennsylvania
A major private research university that receives significant federal R&D funding.
Children's Hospital of Philadelphia
A pediatric healthcare and research institution that has faced recent federal grant cancellations.
University of Pittsburgh
A public research university that is a major recipient of federal research grant funding.
The details
The proposal includes the Sunshine for Researchers Act, which would require scientists receiving federal funds to disclose business sector financial connections. This follows recent instability in the research ecosystem, including the cancellation of nearly 1,400 midstream grants that cost taxpayers roughly $1.3 billion. New policies also target workforce retention through the NIH Mentorship Modernization Act.
Timeline
2003 marks the start of the inflation-adjusted decline in NIH funding.
2008 saw China's R&D spending reach 36% of U.S. levels.
2024 represents the year China's R&D spending reached parity with the U.S.
March 2026 was when Senator McCormick visited the University of Pennsylvania.
July 15, 2026, was the date Children's Hospital of Philadelphia and Pitt researchers were notified of grant cancellations.
Market Landscape
The proposed Sunshine for Researchers Act would mandate new transparency for academic-industry financial ties. This initiative follows a period where R&D competition with China has reached parity, shifting the priority toward domestic research security.
Operators in the biotech and medical research sectors should monitor the disclosure requirements under the proposed Sunshine for Researchers Act for potential compliance impacts. Management should also assess their exposure to federal grant volatility given recent midstream project cancellations.
The takeaway
The move to double NIH funding signals a broader pivot toward state-led industrial policy in the sciences. Stakeholders should track the Sunshine for Researchers Act for upcoming disclosure requirements that may affect future research collaboration and grant eligibility.
Further reading
For more on the changing landscape of medical research and funding, visit the Healthcare section.
Live Poll
Should the federal government double its investment in scientific research to drive medical innovation?
